Outcomes Following OnabotulinumtoxinA Injection for Storage Symptoms in Patients Who Have Been Treated for Prostate Cancer

The authors aimed to evaluate the effectiveness and safety of onabotulinumtoxinA (BTXA) injections for treating storage symptoms in prostate cancer survivors, comparing outcomes based on treatment modalities (radical prostatectomy alone, radiation therapy alone, or both). They found that patients who underwent radical prostatectomy alone had lower rates of repeat BTXA injections and a lower risk of complications compared to those who received combined treatments. Overall, BTXA is a viable option for managing storage symptoms in these patients, but careful patient selection is essential.